Meeting
2024 ASCO Annual Meeting
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor.
Authors
Mitchell Elliott
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Mitchell Elliott , Jesus Fuentes Antras , Sasha Main , Aaron Dou , Nancy Gregorio , Elizabeth Shah , Emily Van de Laar , Geethika Yalamanchili , Leylah Drusbosky , Caroline M. Weipert , Eitan Amir , Michelle B. Nadler , Celeste Yu , Hal K. Berman , Lillian L. Siu , Philippe L. Bedard , David W. Cescon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1043)
DOI
10.1200/JCO.2024.42.16_suppl.1043
Abstract #
1043
Poster Bd #
21
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.
First Author: Joan Albanell
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) monitoring in patients with breast cancer receiving neoadjuvant palbociclib and endocrine therapy: A secondary analysis of the NeoRHEA phase 2 study.
First Author: Alexandra Stanciu
Poster
2023 ASCO Annual Meeting
Clinical application of ctDNA detection in Chinese pediatric patients with soft tissue sarcoma (STS).
First Author: Jia Zhu
Poster
2017 ASCO Annual Meeting
Assessing tumor heterogeneity using circulating tumor DNA to predict and monitor therapeutic response in metastatic breast cancer.
First Author: Fei Ma